Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 5/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uric Acid SCHEMBL3417988 | 0.97 | GDA (1.00) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL22069923 | 0.97 | GDA (1.00) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL7933 | 0.97 | GDA (1.00) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL1071965 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL16213309 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL10631703 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL229866 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL196769 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL2434620 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL7020961 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226839-A1 | SYSTEM AND PROCESS FOR RECLAIMING A METAL-CONTAINING SALT SOLUTION FROM A LITHIUM-CONTAINING BATTERY MATERIAL, AND CHEMICALS THEREOF | eJoule, Inc. | 2024-07-11 | — | — | US | claimed |
| CN-110434326-B | Method for coating lithium aluminum oxide insulating layer on surface of metal soft magnetic powder in situ | 浙江工业大学 | 2021-09-17 | — | — | CN | claimed |
| CN-110434326-A | A kind of method of soft magnetic metal powder surface in-stiu coating lithium aluminum oxide insulating layer | UNIV ZHEJIANG TECHNOLOGY | 2019-11-12 | — | — | CN | claimed |
| US-20240226839-A1 | SYSTEM AND PROCESS FOR RECLAIMING A METAL-CONTAINING SALT SOLUTION FROM A LITHIUM-CONTAINING BATTERY MATERIAL, AND CHEMICALS THEREOF | eJoule, Inc. | 2024-07-11 | — | — | US | disclosed |
| CN-110434326-B | Method for coating lithium aluminum oxide insulating layer on surface of metal soft magnetic powder in situ | 浙江工业大学 | 2021-09-17 | — | — | CN | disclosed |
| CN-110434326-A | A kind of method of soft magnetic metal powder surface in-stiu coating lithium aluminum oxide insulating layer | UNIV ZHEJIANG TECHNOLOGY | 2019-11-12 | — | — | CN | disclosed |
| US-9913831-B2 | Methods and compositions for treating nephrogenic diabetes insipidus | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2018-03-13 | — | — | US | disclosed |
| EP-2750676-B1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | UNIV UTAH RES FOUND (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9539246-B2 | Methods and compositions for treating nephrogenic diabetes insipidus | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160296504-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | UNIVERSITY OF UTAH | 2016-10-13 | — | — | US | disclosed |
| CN-105920605-A | Application of anti-inositol metabolism medicament to establishment of mouse model with NTDs | 王建华 | 2016-09-07 | — | — | CN | disclosed |
| US-8394121-B2 | Intracardiac implant for delivery of alarmins and methods thereof | W.L. GORE & ASSOCIATES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2013033178-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20090182372-A1 | INTRACARDIAC IMPLANT FOR DELIVERY OF ALARMINS AND METHODS THEREOF | W.L. GORE & ASSOCIATES, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20050037450-A1 | Novel targets for lithium therapy | DUKE UNIVERSITY | 2005-02-17 | — | — | US | disclosed |
| WO-2004013152-A2 | NOVEL TARGETS FOR LITHIUM THERAPY | DUKE UNIVERSITY (US) | 2004-02-12 | — | — | WO | disclosed |
| EP-0193061-B1 | VIABILITY TEST DEVICE | MILES INC. (US) | 1990-01-03 | — | — | EP | disclosed |
| US-4683209-A | Viability test device | MILES LABORATORIES, INC. (US) | 1987-07-28 | — | — | US | disclosed |
| US-4649121-A | Viability test device | MILES LABORATORIES, INC. (US) | 1987-03-10 | — | — | US | disclosed |
| EP-0193061-A2 | Viability test device | MILES INC. (US) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296504-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROGENIC DIABETES INSIPIDUS | GPR119, SLC5A2, P2RY2 | GDA 2414/4885ALDH1A1 2394/4885CYP1A2 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.